- Previous Close
30.00 - Open
-- - Bid 10.00 x --
- Ask 20.00 x --
- Day's Range
-- - 52 Week Range
0.15 - 30.00 - Volume
-- - Avg. Volume
0 - Market Cap (intraday)
4.062M - Beta (5Y Monthly) -0.30
- PE Ratio (TTM)
-- - EPS (TTM)
-0.12 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People's Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019. LungLife AI, Inc. was incorporated in 2009 and is based in Thousand Oaks, California.
lunglifeai.com8
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: LLA.L
View More
Performance Overview: LLA.L
Trailing total returns as of 9/12/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LLA.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LLA.L
View MoreValuation Measures
Market Cap
4.06M
Enterprise Value
2.22M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
182.18
Price/Book (mrq)
0.76
Enterprise Value/Revenue
100.18
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.28%
Return on Equity (ttm)
-48.59%
Revenue (ttm)
29k
Net Income Avi to Common (ttm)
-4.47M
Diluted EPS (ttm)
-0.12
Balance Sheet and Cash Flow
Total Cash (mrq)
2.62M
Total Debt/Equity (mrq)
2.66%
Levered Free Cash Flow (ttm)
-2.73M
Company Insights: LLA.L
LLA.L does not have Company Insights